Citius Oncology gets Nasdaq extension to April 19, 2027

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Citius Oncology, Inc. (CTOR) received Nasdaq’s extension through April 19, 2027 to evidence compliance with the $1.00-per-share minimum bid-price requirement for continued listing on the Nasdaq Capital Market. Before that date, the common stock must close at $1.00 per share or more for a minimum of ten consecutive business days to regain compliance.

If Citius Oncology does not regain compliance by April 19, 2027, Nasdaq will notify the company that its common stock is subject to delisting; the company may appeal the determination to a Nasdaq hearings panel. The extension does not change the stock’s current listing, and it continues to trade on the Nasdaq Capital Market. Citius Oncology is evaluating options to regain compliance and says there can be no assurance it will do so.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

None.

Negative

Moderate point. Forward-looking: it has not happened yet and may not happen.Failure to regain compliance by April 19, 2027 prompts a delisting notice.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Minimum closing bid price: $1.00 per share Required compliance period: 10 consecutive business days Compliance extension deadline: April 19, 2027

3 metrics

Minimum closing bid price $1.00 per share Required for continued inclusion on the Nasdaq Capital Market

Required compliance period 10 consecutive business days Closing bid at $1.00 per share or more before April 19, 2027

Compliance extension deadline April 19, 2027 Nasdaq extension to evidence compliance with the Bid Price Rule

Key Terms

Bid Price Rule, Nasdaq hearings panel, continued inclusion

3 terms

Bid Price Rule regulatory

"pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”)"

Nasdaq hearings panel regulatory

"appeal the determination to a Nasdaq hearings panel"

A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

continued inclusion regulatory

"requirement for continued inclusion on the Nasdaq Capital Market"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CTOR’s deadline to regain Nasdaq’s minimum bid-price compliance?

Nasdaq extended Citius Oncology’s compliance period through April 19, 2027. If the common stock closes at $1.00 per share or more for a minimum of ten consecutive business days before then, Nasdaq will confirm compliance in writing.

What happens if CTOR does not meet Nasdaq’s $1.00 bid-price rule?

If Citius Oncology does not regain compliance by April 19, 2027, Nasdaq will provide written notice that its common stock is subject to delisting. The company may appeal the determination to a Nasdaq hearings panel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/23/2026 - 04:10 PM EDT Accepted by SEC EDGAR 10/23/2026 - 04:10 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 19, 2026

Citius Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-41534		99-4362660
(Commission File Number)		(IRS Employer Identification No.)

11 Commerce Drive, 1st Floor, Cranford, NJ		07016
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (908) 967-6677

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CTOR		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On October 19, 2026, Citius Oncology, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted its request for an extension through April 19, 2027 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before April 19, 2027, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance with the Bid Price Rule.

If the Company does not regain compliance with the Bid Price Rule by April 19, 2027, Nasdaq will provide written notice to the Company that its common stock is subject to delisting. At that time, the Company may appeal the determination to a Nasdaq hearings panel.

The Extension Notice has no effect at this time on the listing of the Company’s common stock, which will continue to trade on The Nasdaq Capital Market under the symbol “CTOR”. The Company is currently evaluating its options for regaining compliance. There can be no assurance that the Company will be able to regain compliance with the Bid Price Rule, even if it maintains compliance with the other listing requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CITIUS ONCOLOGY, INC.

Date: October 23, 2026	/s/ Leonard Mazur
	Leonard Mazur
	Chairman and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents